SLC5A2 and chronic kidney disease: The NNTs reported in these studies were 41 with the use of MRA (follow-up period ranged between 24 weeks and 3 years),39 approximately 21 with the use of β-blockers (3-year follow-up period),40 36 with the use of sacubitril valsartan (27-month follow-up period),41 and 17–45 (including the risk of cardiovascular death) with sodium-glucose cotransporter 2 inhibitor treatments (follow-up periods varied across studies).42,43 Similar studies in patients with CKD have not been identified.